Bebtelovimab

Bebtelovimab is a monoclonal antibody developed by AbCellera and Eli Lilly as a treatment for COVID-19.^[2][3][4][5]

Bebtelovimab

Monoclonal antibody
Type	Whole antibody
Source	Human
Target	Spike protein of SARS-CoV-2
Clinical data
Pronunciation	/ˌbɛbtɪˈloʊvɪmæb/ BEB-tih-LOHV-ih-mab[1]
Other names	LY-CoV1404, LY3853113
License data	US DailyMed: Bebtelovimab
Routes of administration	Intravenous
ATC code	None
Legal status
Legal status	US: Withdrawn
Identifiers
KEGG	D12174

Possible side effects include itching, rash, infusion-related reactions, nausea and vomiting.^[2]

Bebtelovimab works by binding to the spike protein of the virus that causes COVID-19, similar to other monoclonal antibodies that have been authorized for the treatment of high-risk people with mild to moderate COVID-19 and shown a benefit in reducing the risk of hospitalization or death.^[2] Bebtelovimab is a neutralizing human immunoglobulin G1 (IgG1) monoclonal antibody, isolated from a patient who has recovered from the Coronavirus disease 2019 (COVID-19), directed against the spike (S) protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for immunization against COVID-19.^[6]

As of November 2022^[update], bebtelovimab is not authorized for emergency use in the US because it is not expected to neutralize Omicron subvariants BQ.1 and BQ.1.1.^[7]

Medical uses

Bebtelovimab was granted an emergency use authorization (EUA) by the US Food and Drug Administration (FDA) in February 2022,^[2] and revoked it in November 2022.^[7] The EUA for bebtelovimab is for the treatment of mild to moderate COVID-19 in people aged 12 years of age and older weighing at least 40 kilograms (88 lb) with a positive COVID-19 test, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by the FDA are not accessible or clinically appropriate.^[2]

Bebtelovimab is not authorized for people who are hospitalized due to COVID-19 or require oxygen therapy due to COVID-19.^[2] Treatment with bebtelovimab has not been studied in people hospitalized due to COVID-19.^[2]

Bebtelovimab is not expected to neutralize Omicron subvariants BQ.1 and BQ.1.1.^[8]

History

Bebtelovimab emerged from a collaboration between Eli Lilly and AbCellera.^[3] Bebtelovimab was discovered by AbCellera and the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center.^[3][4]

Society and culture

Legal status

Bebtelovimab was authorized for medical use in the United States via an emergency use authorization in February 2022.^{[2][9][10][11]}

As of November 2022^[update], bebtelovimab is not authorized for emergency use in the US because it is not expected to neutralize Omicron subvariants BQ.1 and BQ.1.1.^[7][10] Eli Lilly and its authorized distributors have paused commercial distribution of bebtelovimab until further notice by the U.S. Food and Drug Administration (FDA).^[7]

Names

Bebtelovimab is the proposed international nonproprietary name (pINN).^[12]